IL267192A - - Google Patents
Info
- Publication number
- IL267192A IL267192A IL26719219A IL26719219A IL267192A IL 267192 A IL267192 A IL 267192A IL 26719219 A IL26719219 A IL 26719219A IL 26719219 A IL26719219 A IL 26719219A IL 267192 A IL267192 A IL 267192A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170389 | 2016-12-14 | ||
| PCT/KR2017/014727 WO2018111000A1 (ko) | 2016-12-14 | 2017-12-14 | 카바메이트 화합물을 포함하는 비경구용 액상 제제 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL267192A true IL267192A (he) | 2019-07-31 |
| IL267192B1 IL267192B1 (he) | 2023-01-01 |
| IL267192B2 IL267192B2 (he) | 2023-05-01 |
Family
ID=62559693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267192A IL267192B2 (he) | 2016-12-14 | 2019-06-10 | תכשיר נוזלי תוך-ורידי המכיל תרכובת קרבמאט |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12070447B2 (he) |
| EP (1) | EP3556349B1 (he) |
| JP (1) | JP7110196B2 (he) |
| KR (1) | KR102605030B1 (he) |
| CN (2) | CN118766839A (he) |
| AU (1) | AU2017374450B2 (he) |
| CL (1) | CL2019001617A1 (he) |
| DK (1) | DK3556349T3 (he) |
| ES (1) | ES2901427T3 (he) |
| IL (1) | IL267192B2 (he) |
| MX (1) | MX390841B (he) |
| MY (1) | MY200159A (he) |
| PL (1) | PL3556349T3 (he) |
| PT (1) | PT3556349T (he) |
| RU (1) | RU2761041C2 (he) |
| WO (1) | WO2018111000A1 (he) |
| ZA (1) | ZA201903748B (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3711758T3 (fi) | 2017-11-14 | 2024-05-13 | Sk Biopharmaceuticals Co Ltd | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi |
| MX2021003203A (es) * | 2018-09-21 | 2021-05-27 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico. |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060258718A1 (en) * | 2005-04-22 | 2006-11-16 | Choi Yong M | Neurotherapeutic azole compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| CN101309691A (zh) * | 2005-09-30 | 2008-11-19 | 奥瓦什医药品公司 | 新的胃肠外的卡马西平制剂 |
| CN101578103B (zh) * | 2006-06-29 | 2013-09-25 | 林科杰诺米克斯株式会社 | 抗生素的注射剂及其给予液 |
| US8343995B2 (en) * | 2007-04-27 | 2013-01-01 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
-
2017
- 2017-12-14 US US16/468,756 patent/US12070447B2/en active Active
- 2017-12-14 DK DK17880335.9T patent/DK3556349T3/da active
- 2017-12-14 KR KR1020197018404A patent/KR102605030B1/ko active Active
- 2017-12-14 MX MX2019006939A patent/MX390841B/es unknown
- 2017-12-14 ES ES17880335T patent/ES2901427T3/es active Active
- 2017-12-14 PL PL17880335T patent/PL3556349T3/pl unknown
- 2017-12-14 WO PCT/KR2017/014727 patent/WO2018111000A1/ko not_active Ceased
- 2017-12-14 JP JP2019531627A patent/JP7110196B2/ja active Active
- 2017-12-14 CN CN202410768574.7A patent/CN118766839A/zh active Pending
- 2017-12-14 AU AU2017374450A patent/AU2017374450B2/en active Active
- 2017-12-14 CN CN201780077651.2A patent/CN110267647A/zh active Pending
- 2017-12-14 RU RU2019121911A patent/RU2761041C2/ru active
- 2017-12-14 PT PT178803359T patent/PT3556349T/pt unknown
- 2017-12-14 MY MYPI2019003346A patent/MY200159A/en unknown
- 2017-12-14 EP EP17880335.9A patent/EP3556349B1/en active Active
-
2019
- 2019-06-10 IL IL267192A patent/IL267192B2/he unknown
- 2019-06-11 ZA ZA2019/03748A patent/ZA201903748B/en unknown
- 2019-06-12 CL CL2019001617A patent/CL2019001617A1/es unknown
-
2024
- 2024-07-22 US US18/779,456 patent/US20240374568A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060258718A1 (en) * | 2005-04-22 | 2006-11-16 | Choi Yong M | Neurotherapeutic azole compounds |
Non-Patent Citations (1)
| Title |
|---|
| RAJEWSKI R A ET AL,, PHARMACEUTICAL APPLICATIONS OF CYCLODEXTRINS. 2. IN VIVO DRUG DELIVERY, 1 November 1996 (1996-11-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118766839A (zh) | 2024-10-15 |
| RU2019121911A (ru) | 2021-01-15 |
| BR112019011914A2 (pt) | 2019-11-05 |
| CL2019001617A1 (es) | 2019-08-23 |
| JP2020502108A (ja) | 2020-01-23 |
| IL267192B2 (he) | 2023-05-01 |
| RU2019121911A3 (he) | 2021-03-05 |
| AU2017374450B2 (en) | 2023-05-11 |
| WO2018111000A1 (ko) | 2018-06-21 |
| US12070447B2 (en) | 2024-08-27 |
| MY200159A (en) | 2023-12-09 |
| JP7110196B2 (ja) | 2022-08-01 |
| KR102605030B1 (ko) | 2023-11-23 |
| MX390841B (es) | 2025-03-21 |
| CN110267647A (zh) | 2019-09-20 |
| PL3556349T3 (pl) | 2022-04-11 |
| IL267192B1 (he) | 2023-01-01 |
| PT3556349T (pt) | 2021-12-28 |
| US20240374568A1 (en) | 2024-11-14 |
| RU2761041C2 (ru) | 2021-12-02 |
| EP3556349A4 (en) | 2020-07-01 |
| ES2901427T3 (es) | 2022-03-22 |
| AU2017374450A1 (en) | 2019-07-04 |
| EP3556349A1 (en) | 2019-10-23 |
| DK3556349T3 (da) | 2022-01-03 |
| ZA201903748B (en) | 2020-12-23 |
| KR20190087568A (ko) | 2019-07-24 |
| US20190314336A1 (en) | 2019-10-17 |
| EP3556349B1 (en) | 2021-11-24 |
| CA3046458A1 (en) | 2018-06-21 |
| MX2019006939A (es) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002665A2 (he) | ||
| BR112018004986A2 (he) | ||
| BR112019008105A2 (he) | ||
| BR112019001429A2 (he) | ||
| RU2019121911A3 (he) | ||
| BR212018070320U2 (he) | ||
| BR112019011044B1 (pt) | Compostos de pirazol substituído, seu uso, e composição farmacêutica | |
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112019000061B1 (pt) | Comutação e modulação de splicing de pré-mrna compreendendo porções de arcabouço bicíclico, com características melhoradas para o tratamento de distúrbios genéticos | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR112018072681B1 (pt) | Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR112019006736A2 (he) | ||
| BR122022020382A2 (he) | ||
| BE2016C016I2 (he) | ||
| CN303536231S (he) | ||
| CN303584020S (he) | ||
| CN303536207S (he) | ||
| CN303536221S (he) | ||
| CN303536111S (he) | ||
| CN303604692S (he) | ||
| CN303537291S (he) | ||
| CN303586550S (he) |